IRB#11848 A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are Planned to Undergo Enucleation

IRB#16661 A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

IRB#1625 A Phase 1b/2, Open-label, Dose-escalation and Expansion Trial of Tumor Injections of SD-101 with Pembrolizumab in Patients with Metastatic Melanoma

IRB#16198 A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides Compared to IMCgp100 Alone

IRB#16225 A Phase Ib/Ii Open-label Study of IMCgp100 + Durvalumab or Durvalumab + Tremelimumab Compared to IMCgp100 Alone

IRB#15298 Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With BRAFV600 Mutant Melanoma

Please refer to Phase I studies for more clinical trial opportunities

http://www.ohsu.edu/research/rda/so/knight.php